Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Accured Expenses (2016 - 2025)

IGC Pharma (IGC) has disclosed Change in Accured Expenses for 13 consecutive years, with $93000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 70.57% to $93000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.2 million, a 344.05% decrease, with the full-year FY2025 number at -$196000.0, down 199.49% from a year prior.
  • Change in Accured Expenses was $93000.0 for Q3 2025 at IGC Pharma, up from -$599000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $484000.0 in Q1 2023 to a low of -$599000.0 in Q2 2025.
  • A 4-year average of -$3714.3 and a median of $59500.0 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 236.17% in 2024, then crashed 496.69% in 2025.
  • IGC Pharma's Change in Accured Expenses stood at -$30000.0 in 2021, then plummeted by 793.33% to -$268000.0 in 2023, then rose by 19.4% to -$216000.0 in 2024, then surged by 143.06% to $93000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Change in Accured Expenses are $93000.0 (Q3 2025), -$599000.0 (Q2 2025), and -$447000.0 (Q1 2025).